Shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) have earned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 12-month consensus target price of $5.10 for the company and are forecasting that the company will post ($0.19) EPS for the current quarter, according to Zacks. Zacks has also assigned ESSA Pharma an industry rank of 110 out of 265 based on the ratings given to its competitors.

A number of analysts have recently weighed in on EPIX shares. Zacks Investment Research raised shares of ESSA Pharma from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 18th. ValuEngine downgraded shares of ESSA Pharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 7th. Bloom Burton reaffirmed a “buy” rating on shares of ESSA Pharma in a research report on Thursday, May 18th. Finally, Dawson James reaffirmed a “buy” rating on shares of ESSA Pharma in a research report on Thursday, August 3rd.

ILLEGAL ACTIVITY NOTICE: “Zacks: ESSA Pharma Inc. (EPIX) Given Average Rating of “Strong Buy” by Analysts” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at

Shares of ESSA Pharma (NASDAQ:EPIX) traded up 11.136% on Friday, reaching $0.489. 1,166,006 shares of the company traded hands. ESSA Pharma has a one year low of $0.25 and a one year high of $3.59. The stock’s 50 day moving average price is $0.35 and its 200-day moving average price is $1.43. The stock’s market capitalization is $14.23 million.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with's FREE daily email newsletter.